PT  - JOURNAL ARTICLE
AU  - Chin-Fu Liu
AU  - Johnny Hsu
AU  - Xin Xu
AU  - Sandhya Ramachandran
AU  - Victor Wang
AU  - Michael I. Miller
AU  - Argye E. Hillis
AU  - Andreia V. Faria
AU  - the STIR and VISTA Imaging investigators
TI  - Deep learning-based detection and segmentation of diffusion abnormalities in acute ischemic stroke
AID  - 10.1101/2021.10.19.21257543
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.19.21257543
4099  - http://medrxiv.org/content/early/2021/10/19/2021.10.19.21257543.short
4100  - http://medrxiv.org/content/early/2021/10/19/2021.10.19.21257543.full
AB  - Background Accessible tools to efficiently detect and segment diffusion abnormalities in acute strokes are highly anticipated by the clinical and research communities.Methods We developed a tool with deep learning networks trained and tested on a large dataset of 2,348 clinical diffusion weighted MRIs of patients with acute and sub-acute ischemic strokes, and further tested for generalization on 280 MRIs of an external dataset (STIR).Results Our proposed model outperforms generic networks and DeepMedic, particularly in small lesions, with lower false positive rate, balanced precision and sensitivity, and robustness to data perturbs (e.g., artefacts, low resolution, technical heterogeneity). The agreement with human delineation rivals the inter-evaluator agreement; the automated lesion quantification of volume and contrast has virtually total agreement with human quantification.Conclusion Our tool is fast, public, accessible to non-experts, with minimal computational requirements, to detect and segment lesions via a single command line. Therefore, it fulfills the conditions to perform large scale, reliable and reproducible clinical and translational research.Plain Language Summary Quantifying the volume and location of lesions caused by acute ischemic strokes is crucial for therapeutics and prognostic assessment. Research wise, it can be a window to observe relationships between anatomy and function. The definition of such lesions, mostly made by humans, is time- and work-consuming and uses subjective criteria. We used artificial intelligence in a large database of MRIs of patients with ischemic stroke to create an automated tool to detect and segment lesions derived from acute stroke. It outputs the lesion volumes and 3D segmentation maps. Our tool is fast, public, accessible to non-experts, run in local computers, with minimal computational requirements, fulfilling the conditions to perform large scale, reliable and reproducible clinical and translational research.Competing Interest StatementMichael I. Miller owns "AnatomyWorks". This arrangement is being managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.Funding StatementThis research was supported in part by the National Institute of Deaf and Communication Disorders, NIDCD, through R01 DC05375, R01 DC015466, P50 DC014664 (AH), the National Institute of Biomedical Imaging and Bioengineering, NIBIB, through P41 EB015909 (MIM), and the National Institute of Neurological Disorders and Stroke, NINDS (STIR / Vista Imaging Investigators).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We have complied with all relevant ethical regulations and the guidelines of the Johns Hopkins Institutional Review Board, that approved this study. We have complied with all relevant STIR regulations for data usage.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe tool described in this study is publicly available at https://www.nitrc.org/projects/ads https://www.nitrc.org/projects/ads/